IRCT20130917014693N10招募中3 期
Evaluation the efficacy and safety of Hydroxychloroquine administration for COVID-19 post exposure prophylaxis
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Age over 18 years old
- •Close contact with COVID-19 patient at least in past 4 days
- •sign the informed consent form to participate in study
排除标准
- •Pervious case of COVID-19
- •Current case of COVID-19
- •Presenting influenza like symptoms (fever, cough, and sore throat) in last 30 days
- •Travel history in last 14 days
- •Lactation and pregnancy
- •History of arrhythmia
- •Drug allergy history
- •Favism history
- •Chronic liver disease
- •Chronic kidney disease
- •Retinopathy history
- •Weight under 40 kg
- •Patients who are receiving arritmogenica medicines
研究者
相似试验
招募中
3 期
Treatment of Hydroxychloroquine in Type 2 Diabetes Patients Uncontrolled on Metformin MonotherapyCTRI/2021/11/037750Ipca Laboratories Ltd
招募中
1 期
Efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19COVID-19.COVID-19U07.1IRCT20150808023559N20Ardabil University of Medical Sciences100
已完成
3 期
Comparison of the safety and efficacy of Favipiravir and kaletra in COVID-19IRCT20200318046812N1Iran University of Medical Sciences324
招募中
4 期
A Clinical Trial to Study the Safety and Efficacy of Hydroxychloroquine in Patients with Type-2 DaibetesCTRI/2016/02/006599Ipca Laboratories Ltd600
招募中
2 期
Combination therapy in COVID 19COVID-19 pneumonia.IRCT20100228003449N30Tehran University of Medical Sciences50